Zealand's (ZEAL) glepaglutide SBS Readout is Inflection Points for Stock - Needham & Company Reiterates Buy Rating and $32 Price Target
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $32.00 price target on Zealand Pharma A/S (NASDAQ: ZEAL) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
